Tetra Bio Pharma Strengthens Product Pipeline Via Co-Development Agreement

Tetra Bio Pharma (TSXV: TBP) has strengthened its product pipeline as of this morning, providing the company with new potential drug candidates following the approval of Caumz and Qixleef for marketing by the appropriate health agencies. The company has signed a co-development agreement with that of MAKScientific to enable the access to novel patented drug molecules.

The definitive co-development agreement will enable Tetra to have access to new patented molecules with CB1 and CB2 agonist or antagonist profiles. The access to the molecules will enable Tetra to remain focused on its goal of utilizing the endocannabinoid system to provide health care solutions.

MAKScientific has developed a pipeline of small molecule drugs that interact with the CB1 and CB2 receptors within the endocaannabinoid system. Under the agreement, MAKScientific will continue to develop new molecules that will then be screened by Tetra for the potential to use the molecules to combat pain, cancer, inflammation as well as other potential targets of interest.

A successful Biopharmaceutical company requires a pipeline of patent protected molecules that can become its next generation therapeutics. Patent protection is one of the most important aspects to safeguarding the company’s assets and its shareholders investments.

Dr. Guy Chamberland, CEO and CRO of Tetra

Tetra Bio Pharma last traded at $0.36 on the TSX Venture.


Information for this briefing was found via Sedar and Tetra Bio-Pharma Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

Tetra Bio-Pharma Subsidiary Conducts Financing for Hemp Energy Drink

Tetra Bio-Pharma (TSXV: TBP) announced this morning that a subsidiary of the firm has obtained...

Monday, November 18, 2019, 08:54:24 AM

Tetra Bio Pharma Sees Two Products Approved By Health Canada

As The Deep Dive reported on late yesterday afternoon, Tetra Bio Pharma (TSXV: TBP) has...

Friday, January 17, 2020, 09:31:54 AM

Tetra Bio-Pharma Signs Manufacturing Agreement with Vitiprints

Tetra Bio-Pharma Inc. (TSXV: TBP) has entered into a manufacturing agreement with Vitiprints LLC, which...

Thursday, February 13, 2020, 01:46:29 PM

Tetra Bio Pharma Sees Drug Approved By Health Canada

Tetra Bio Pharma (TSXV: TBP) is currently seeing upward price momentum on the discovery that...

Thursday, January 16, 2020, 03:42:12 PM

Tetra Bio-Pharma Releases Update Regarding its Veterinary Clinical Study

Tetra Bio-Pharma Inc (TSXV: TBP) has released an update regarding its clinical study for the...

Wednesday, January 29, 2020, 08:55:32 AM